Ocugen Provides Business Update with First Quarter 2024 Financial Results
May 14, 2024 08:00 ET
|
Ocugen
All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 Biologics License Application (BLA) and Market...
Global Cell Therapy and Gene Therapy Market Report 2023-2029
May 13, 2024 11:34 ET
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029" report has been added to ResearchAndMarkets.com's offering.A newly released...
Global Xerostomia Therapeutics Analysis & Forecast to 2024-2034: $3.69 Billion Market Expanding Amid Growing Cases of Parkinson's, Hypertension, and Diabetes
May 13, 2024 05:51 ET
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Global Xerostomia Therapeutics Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global...
Ocugen to Present at May 2024 Investor Conferences
May 10, 2024 07:45 ET
|
Ocugen
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
May 09, 2024 16:05 ET
|
Adverum Biotechnologies, Inc.
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments...
Global Cell and Gene Therapy in Ophthalmology Research Report 2024: Market Anticipated to Soar with Projected CAGR Growth of 50.8% by 2029
May 09, 2024 09:43 ET
|
Research and Markets
Dublin, May 09, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapies in Ophthalmology" report has been added to ResearchAndMarkets.com's offering.Despite the high cost of therapies, linked to the...
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
May 08, 2024 11:00 ET
|
Siren Biotechnology, Inc.
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 07, 2024 07:05 ET
|
uniQure Inc.
uniQure announces first quarter 2024 results
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
May 07, 2024 06:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
May 07, 2024 03:00 ET
|
Coave Therapeutics
Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month follow-up Phase I/II results will be discussed with US and...